Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Clin Infect Dis. 2024 Oct 15;79(4):1018-1023. doi: 10.1093/cid/ciae308.
The immunocompromised population was disproportionately affected by the severe acute respiratory syndrome coronavirus 2 pandemic. However, these individuals were largely excluded from clinical trials of vaccines, monoclonal antibodies, and small molecule antivirals. Although the community of scientists, clinical researchers, and funding agencies have proven that these therapeutics can be made and tested in record time, extending this progress to vulnerable and medically complex individuals from the start has been a missed opportunity. Here, we advocate that it is paramount to plan for future pandemics by investing in specific clinical trial infrastructure for the immunocompromised population to be prepared when the need arises.
免疫功能低下人群在严重急性呼吸综合征冠状病毒 2 大流行中受到不成比例的影响。然而,这些人在很大程度上被排除在疫苗、单克隆抗体和小分子抗病毒药物的临床试验之外。尽管科学界、临床研究人员和资助机构已经证明可以在创纪录的时间内制造和测试这些疗法,但从一开始就将这一进展扩大到脆弱和医疗复杂的人群是一个错失的机会。在这里,我们主张,通过投资于免疫功能低下人群的特定临床试验基础设施,为未来的大流行做好准备,这是至关重要的。